Ryvu Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate Update
Ryvu Therapeutics Named the Stock Exchange Company of the Year
Ryvu Therapeutics to Participate in The Leukemia & Lymphoma Society Therapy Acceleration Program® (LLS TAP) Panel and 12th Annual LifeSci Partners Corporate Access Event
What we do
We challenge current treatment paradigms
At Ryvu, we develop therapeutics that address clinical limitations of current treatments in oncology.
Our pipeline includes candidates with differentiated properties from kinase, synthetic lethality, and immuno-oncology programs.
Ryvu Therapeutics (Selvita Oncology) was founded in 2007. Since 2014, the company has been listed on Warsaw Stock Exchange under the ticker RVU.
Ryvu Therapeutics is organized for highly efficient R&D driven by breakthrough science, aiming to realize full value potential for its shareholders, partners and employees.See More
59.20 PLN -1.50% RVU • 30/03/2023 17:00 • Warsaw Stock Exchange